Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

New therapeutic approaches for spondyloarthritis.

Manadan AM, James N, Block JA.

Curr Opin Rheumatol. 2007 May;19(3):259-64. Review.

PMID:
17414952
2.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
3.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

4.

Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.

Kavanaugh A, Tutuncu Z, Catalan-Sanchez T.

Curr Opin Rheumatol. 2006 Jul;18(4):347-53. Review.

PMID:
16763453
5.

Ankylosing spondylitis: new treatment modalities.

Brandt J, Marzo-Ortega H, Emery P.

Best Pract Res Clin Rheumatol. 2006 Jun;20(3):559-70. Review.

PMID:
16777582
6.

Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.

Henderson C, Davis JC.

Nat Clin Pract Rheumatol. 2006 Apr;2(4):211-8. Review.

PMID:
16932687
7.

Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?

Haibel H, Sieper J.

Curr Opin Rheumatol. 2010 Jul;22(4):388-92. doi: 10.1097/BOR.0b013e32833aaf93. Review.

PMID:
20473176
8.

Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.

Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.

Ann Rheum Dis. 2010 Jun;69(6):1065-71. doi: 10.1136/ard.2009.111187. Epub 2009 Sep 9.

PMID:
19740906
9.

Anti-TNF-alpha therapy in ankylosing spondylitis.

De Keyser F, Van den Bosch F, Mielants H.

Cytokine. 2006 Mar 7;33(5):294-8. Epub 2006 Mar 3. Review.

PMID:
16516484
10.

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.

Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.

Ann Rheum Dis. 2008 Sep;67(9):1276-81. Epub 2007 Nov 15.

PMID:
18006539
11.

TNF antagonists for ankylosing spondylitis.

[No authors listed]

Drug Ther Bull. 2005 Mar;43(3):19-22. Review.

PMID:
15762384
12.

Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H.

Ann Rheum Dis. 2002 Dec;61 Suppl 3:iii51-60. Review.

13.

Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.

Song IH, Maksymowych WP.

Rheum Dis Clin North Am. 2012 Aug;38(3):613-33. doi: 10.1016/j.rdc.2012.08.004. Epub 2012 Sep 15. Review.

PMID:
23083759
14.

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Gorman JD, Sack KE, Davis JC Jr.

N Engl J Med. 2002 May 2;346(18):1349-56.

15.

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2005 Dec 15;53(6):856-63.

16.

[Anti-TNF alfa therapy in ankylosing spondylitis].

Cravo AR, Tavares V, Da Silva JC.

Acta Med Port. 2006 Mar-Apr;19(2):141-50. Epub 2006 Aug 18. Review. Portuguese.

17.

The anti-TNF revolution in ankylosing spondylitis: patients with severe disease now have access to promising new drugs.

Schachna L.

Med J Aust. 2004 Nov 15;181(10):529-30. No abstract available.

PMID:
15540959
18.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

PMID:
22563743
19.

Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.

Sieper J, Appel H, Braun J, Rudwaleit M.

Arthritis Rheum. 2008 Mar;58(3):649-56. doi: 10.1002/art.23260. Review. No abstract available.

20.

Efficacy of incentive spirometer exercise on pulmonary functions of patients with ankylosing spondylitis stabilized by tumor necrosis factor inhibitor therapy.

So MW, Heo HM, Koo BS, Kim YG, Lee CK, Yoo B.

J Rheumatol. 2012 Sep;39(9):1854-8. doi: 10.3899/jrheum.120137. Epub 2012 Aug 1.

PMID:
22859343

Supplemental Content

Support Center